Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1995 1
1997 1
2003 2
2004 1
2005 1
2006 2
2007 2
2008 1
2009 2
2010 2
2012 1
2013 2
2014 5
2015 5
2016 3
2017 4
2018 5
2019 4
2020 4
2021 9
2022 7
2023 5
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. Among authors: hamlin pa. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Evens AM, et al. Among authors: hamlin pa. J Clin Oncol. 2018 Oct 20;36(30):3015-3022. doi: 10.1200/JCO.2018.79.0139. Epub 2018 Sep 4. J Clin Oncol. 2018. PMID: 30179569 Clinical Trial.
Retrospective characterization of nodal marginal zone lymphoma.
Stuver R, Drill E, Qualls D, Okwali M, Lee Batlevi C, Caron PC, Dogan A, Epstein-Peterson ZD, Falchi L, Hamlin PA, Horwitz SM, Imber BS, Intlekofer AM, Johnson WT, Khan N, Kumar A, Lahoud OB, Lue JK, Matasar MJ, Moskowitz AJ, Noy A, Owens CN, Palomba ML, Schöder H, Vardhana SA, Yahalom J, Zelenetz AD, Salles G, Straus DJ. Stuver R, et al. Among authors: hamlin pa. Blood Adv. 2023 Sep 12;7(17):4838-4847. doi: 10.1182/bloodadvances.2022009587. Blood Adv. 2023. PMID: 37307213 Free PMC article. Review.
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Batlevi CL, et al. Among authors: hamlin pa. Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z. Blood Cancer J. 2020. PMID: 32678074 Free PMC article.
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
Gurumurthi A, Bantilan KS, Hamlin PA, Kumar A, Matasar M, Zhu M, Joseph A, Castro A, Biggar E, Salles G, Zelenetz AD, von Keudell G. Gurumurthi A, et al. Among authors: hamlin pa. Leuk Lymphoma. 2024 Dec;65(14):2224-2227. doi: 10.1080/10428194.2024.2398658. Epub 2024 Sep 20. Leuk Lymphoma. 2024. PMID: 39303057 No abstract available.
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, Munoz J, Hamlin PA, Kim YH, Wilcox RA, Patel MR, Coffey G, Innes A, Betz A, Holland J, Guzman CB, Smith SM. Horwitz SM, et al. Among authors: hamlin pa. Leuk Lymphoma. 2025 Jun;66(6):1100-1110. doi: 10.1080/10428194.2025.2455489. Epub 2025 Feb 8. Leuk Lymphoma. 2025. PMID: 39921522 Free article. Clinical Trial.
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.
Luttwak E, Robin ET, Drill E, Boardman A, Caron P, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin PA, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Steiner R, Stuver R, Torka P, Vardhana S, Zelenetz AD, Salles G, Moskowitz CH, Moskowitz AJ. Luttwak E, et al. Among authors: hamlin pa. Leuk Lymphoma. 2025 Jul;66(7):1276-1283. doi: 10.1080/10428194.2025.2465553. Epub 2025 Mar 1. Leuk Lymphoma. 2025. PMID: 40598813
68 results